Visitor information – Everything you need to know about visiting our sites.
Alfred Health research outcomes are published in a wide range of peer reviewed journals.
Search or browse research publications by year, research area, publication type or keyword.
Publication Details
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapi
(2016), BMC Cancer, 16,
A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer
Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D, Strickland A, Franco M, Blum R, Johnson C, Ganju V, Shapiro J, Chong G, Charlton J, Haydon A, Schofield P
(2016), Oncologist, 21(8),
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelste
(2016), Sci Transl Med, 8(346),
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists
Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J
(2016), Asia Pac J Clin Oncol, 12 Suppl 7,
Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma
Voskoboynik M, Mar V, Mailer S, Colebatch A, Fennessy A, Logan A, Hewitt C, Cebon J, Kelly J, McArthur G
(2016), Pigment Cell Melanoma Res, 29(2),
Challenges of patient selection for Phase I oncology trials
Voskoboynik M, Arkenau H-T
(2015), In: Vallisuta O, Olimat S (eds), Drug Discovery and Development - From Molecules to Medicine, InTech, Croatia, Chapter 3, 65-82
Advanced melanoma: the changing landscape of treatment
Haydon A, Moore M
(2015), Med Today, 16(9), 58-61
Long survival (cure) to cisplatin/infusional 5-flurouracil in metastatic squamous cell anal cancer with extensive liver and lung metastases
Haydon A, Tay R, Mak G, Shapiro J
(2015), Case Rep Clin Med, 4(3), 73-6
Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
Klein O, Davis ID, McArthur GA, Chen L, Haydon A, Parente P, Dimopoulos N, Jackson H, Xiao K, Maraskovsky E, Hopkins W, Stan R, Chen W, Cebon J
(2015), Cancer Immunol Immunother, 64(4), 507-18
A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A
(2015), Ann Oncol, 26(11), 2267-74
Prognosis associated with cutaneous melanoma metastases
Pan Y, Haydon AM, McLean CA, McDonald PB, Kelly JW
(2015), Australas J Dermatol, 56(1), 25-8
Principles of Medical Therapy
George M, Schwarz M, McKinnon R
(2014), In: Sabesan S, Olver I (eds), Clinical Oncology for Medical Students. Sydney: Cancer Council Australia, Chapter 10,
Ideal care and the realities of practice: interdisciplinary relationships in the management of advanced cancer patients in Australian emergency departments
Lane H, Weil J, Jelinek GA, Boughey M, Marck CH, Weiland TJ, Haydon A, Philip J
(2014), Support Care Cancer, 22(4), 1029-35
The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry
Stirling RG, Evans SM, McLaughlin P, Senthuren M, Millar J, Gooi J, Irving L, Mitchell P, Haydon A, Ruben J, Conron M, Leong T, Watkins N, McNeil JJ
(2014), Lung, 192(5), 749-58
Intended follow up of women with breast cancer at low risk of recurrence and at least 5 years from diagnosis
Bell RJ, Fradkin P, Robinson PJ, Schwarz M, Davis SR
(2014), Intern Med J, 44(4), 332-8
A comparison of the characteristics, treatment and outcome after 5 years, of Australian women aged 70+ with those aged >70 years at the time of diagnosis of breast cancer
Panjari M, Robinson PJ, Davis SR, Schwarz M, Bell RJ
(2014), J Geriatr Oncol, 5(2), 141-7
Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment
Bell RJ, Robinson PJ, Nazeem F, Panjari M, Fradkin P, Schwarz M, Davis SR
(2014), J Cancer Surviv, 8(1), 1-8
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ
(2013), J Clin Oncol, 31(19), 2477-84
Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype
Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, Haydon AM, Rosty C, English DR, Giles GG, McGuckin MA, Young JP, Buchanan DD
(2013), Mod Pathol, 26(12), 1642-56
Size of anal squamous cell carcinomas at diagnosis: a retrospective case series
Read TR, Huson KL, Millar JL, Haydon A, Porter IW, Grulich AE, Hocking JS, Chen MY, Bradshaw CS, Fairley CK
(2013), Int J STD AIDS, 24(11), 879-82